Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
34 hedge funds and large institutions have $4.41M invested in Clearside Biomedical in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 20 closing their positions.
1% more capital invested
Capital invested by funds: $4.38M → $4.41M (+$25.9K)
0.44% more ownership
Funds ownership: 0.8% → 1.23% (+0.44%)
32% less funds holding
Funds holding: 50 → 34 (-16)
45% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 11
80% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$3.58M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$105K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$40.5K |
| 4 |
JIC
Johnson Investment Counsel
Cincinnati,
Ohio
|
+$19.1K |
| 5 |
VF
Virtu Financial
New York
|
+$10.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$223K |
| 2 |
Millennium Management
New York
|
-$205K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$123K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$122K |
| 5 |
Goldman Sachs
New York
|
-$119K |
CLSD Hedge Fund Activity: Q3 2019 in Review
34 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q3 2019, worth a combined $4.41M — up 0.59% from $4.38M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of CLSD and 4 opened new positions — a net loss of 16 holders — while 11 trimmed existing stakes and 6 added.
The largest buyer was RTW Investments, opening a new position worth an estimated $3.58M. The largest seller was Northern Trust, cutting an estimated $223K.
- 34 institutional investors held Clearside Biomedical (CLSD) as of Q3 2019, down from 50 in Q2 2019.
- Funds reported $4.41M of Clearside Biomedical stock for Q3 2019, up 0.59% quarter-over-quarter.
- 4 funds opened new Clearside Biomedical positions in Q3 2019 and 20 closed out, a net change of -16 holders.
- The largest Clearside Biomedical buyer in Q3 2019 was RTW Investments, an estimated $3.58M added.
- The largest Clearside Biomedical seller in Q3 2019 was Northern Trust, an estimated $223K sold.
Based on aggregated 13F filings for Q3 2019.